Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma
Frontiers in Oncology · 24.08.2026 · 16
DOI: 10.3389/fonc.2026.1921922 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 24.08.2026. Verfasst von Zelin Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Although CD19 CAR-T cell therapy has improved outcomes in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), responses are variable and predictive biomarkers are lacking. The triglyceride glucose-body mass index (TyG-BMI)—a surrogate of insulin resistance—has shown prognostic value in solid tumors, but its relevance to DLBCL and CAR-T efficacy remains unknown.
Methods
We retrospectively analyzed 204 newly diagnosed DLBCL patients treated with rituximab-containing regimens, stratified by median TyG-BMI. Prognostic associations were assessed by Kaplan-Meier and multivariate Cox regression, and a nomogram was constructed. In an exploratory sub-analysis, 20 patients who received CD19 CAR-T therapy were assessed. CAR-T cell persistence was measured by flow cytometry one week post-infusion and correlated with pre-infusion TyG-BMI by Pearson analysis. CRS and ICANS were graded per ASTCT criteria. Post-CAR-T survival was compared by Kaplan-Meier analysis stratified by median pre-infusion TyG-BMI.
Results
High TyG-BMI was independently associated with poorer PFS (HR, 2.146; 95% CI, 1.092–4.214; P = 0.027) and OS (HR, 2.531; 95% CI, 1.084–5.913; P = 0.032), and further stratified risk within IPI risk groups and across disease stages. A nomogram incorporating TyG-BMI, IPI, and bone marrow involvement predicted 1-, 3-, and 5-year OS (AUC: 0.886, 0.799, 0.772). In the CAR-T subcohort ( n = 20), elevated pre-infusion TyG-BMI was significantly inversely correlated with CAR-T cell persistence at one week post-infusion ( r = -0.570, P = 0.009). Patients with high pre-infusion TyG-BMI experienced inferior responses to CAR-T therapy, with shorter median PFS (5.0 vs. 19.5 months) and OS (39.0 vs. 81.0 months) compared with the low TyG-BMI group.
Conclusion
TyG-BMI is an independent prognostic factor in DLBCL that refines IPI-based stratification, and elevated pre-infusion TyG-BMI is associated with attenuated CAR-T cell persistence and inferior outcomes. This readily available metabolic index may aid risk assessment and treatment planning in DLBCL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Hematology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
- Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
- Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
- Weifang Yidu Central Hospital, Qingzhou, Shandong, China.
Zitieren
APA
Liu, Z., Yang, R., Chen, J., Liu, Z., Ding, Y., Huang, K., Liao, Y., Hu, L., Pu, L., Liu, L., Wang, J., Tao, Q., & Xiong, S. (2026). Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1921922
Vancouver
Liu Z, Yang R, Chen J, Liu Z, Ding Y, Huang K, et al. Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1921922
BibTeX
@article{Liu2026,
author = {Liu, Zelin and Yang, Ruijun and Chen, Jiawen and Liu, Ziyu and Ding, Yangyang and Huang, Keke and Liao, Ya and Hu, Linhui and Pu, Lianfang and Liu, Lujie and Wang, Jiyu and Tao, Qianshan and Xiong, Shudao},
title = {Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1921922}
}
EUVIMED